Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea

Inclusion criteria: * Newly diagnosed as essential hypertension or not treated in the past 2 weeks(If the subject took medication in the past 2 weeks, a wash-out period of at least 2 weeks will be completed prior to performing screening (week -2) assessments) * Mean seated SBP at screen visit = 130mmHg (as measured by a mercury sphygmomanometer) * Type 2 diabetes (American Diabetes Association criteria 2004) and HbA1C \<11% * Agree to practice acceptable contraceptive measures during the study, and for 30 days after the last dose of study medication is taken if the subject a female of child-bearing potential * Provide written informed consent Exclusion criteria: * Mean seated SBP of \> 180 mmHg * Known or suspected secondary hypertension * Anemia defined by haemoglobin concentration \< 10.0 g/dL * Hemoglobinopathy or peripheral vascular disease * Clinically significant renal or hepatic disease (i.e., subjects with serum creatinine = 2.0 mg/dL; Alanine aminotransferase, Aspartate aminotransferase, total bilirubin, or alkaline phosphatase \> 2.5 times the upper limit of the normal reference range) * Unstable or severe angina, coronary insufficiency, or any congestive heart failure requiring pharmacologic treatment * Chronic disease requiring intermittent or chronic treatment with oral, intravenous, or intra-articular corticosteroids (i.e. only use of topical, inhaled or nasal corticosteroids is permissible) * Female who is lactating, pregnant, or planning to become pregnant * clinically significant abnormality identified at screening which in the judgement of the investigator makes the subject unsuitable for inclusion in the study (e.g. physical examination, laboratory tests, or electrocardiogram etc.) * Acute or chronic metabolic acidosis or a history of diabetic ketoacidosis